Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

ClinicalTrials.gov ID: NCT04402489

Public ClinicalTrials.gov record NCT04402489. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jun 26, 2026, 7:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria

Study identification

NCT ID: NCT04402489
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Tanabe Pharma America, Inc.; Industry
Enrollment: 184 participants

Conditions and interventions

Conditions

Interventions

Placebo Drug
MT-7117 Low Dose Drug
MT-7117 High Dose Drug

Drug

Eligibility (public fields only)

Age range: 12 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 31, 2020
Primary completion: Dec 13, 2021
Completion: Jul 25, 2022
Last update posted: Dec 29, 2025

2020 – 2022

United States locations

U.S. sites: 10
U.S. states: 10
U.S. cities: 10

Facility	City	State	ZIP	Site status
Marvel Clinical Research, LLC	Huntington Beach	California	92647	—
University Of Miami School Of Medicine, Center For Liver Diseases	Miami	Florida	33136	—
MetroBoston Clinical Partners, LLC	Brighton	Massachusetts	02135	—
Kansas City Research Institute	Kansas City	Missouri	64131	—
Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH)	New York	New York	10029	—
Wake Forest University Baptist Health	Winston-Salem	North Carolina	27109	—
Remington-Davis Clinical Research	Columbus	Ohio	43215	—
Thomas Jefferson University	Philadelphia	Pennsylvania	19107	—
The University of Texas Medical Branch (UTMB)	Galveston	Texas	77555	—
University of Washington-Seattle Cancer Care Alliance	Seattle	Washington	19023	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04402489, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 29, 2025 · Synced Jun 26, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04402489 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →